|

Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma

RECRUITINGSponsored by Sahlgrenska University Hospital
Actively Recruiting
SponsorSahlgrenska University Hospital
Started2025-03-31
Est. completion2028-12
Eligibility
Age15 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07585032

Summary

Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies. In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.

Eligibility

Age: 15 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Insulinoma verified by pathology (often from EUS-FNB-sampling)

Exclusion Criteria:

* Patients unwilling to participate
* Patients unable to understand and obtain written informed conscent
* Severe comorbidity

Conditions2

CancerInsulinoma; Pancreas

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.